The Cancer Letter

Inside information on cancer research and drug development

Clinical

Daily oral edoxaban met primary endpoint in Hokusai-VTE cancer study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Hokusai-VTE CANCER study evaluating oral edoxaban (known as Savaysa in the U.S. and Lixiana outside the U.S.) found edoxaban to be non-inferior to subcutaneous injectable LMWH dalteparin for the treatment of cancer-associated VTE or major bleeding.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Balance, gait negatively impacted after chemotherapy

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Table of Contents

Login

Looking for IP Login?